Skip Navigation

British Journal of Anaesthesia 2008 100(5):729-730; doi:10.1093/bja/aen066
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Alguacil, L. F.
Right arrow Articles by Morales, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alguacil, L. F.
Right arrow Articles by Morales, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2008. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Subcutaneous tetrodotoxin and inflammatory pain

L. F. Alguacil*, C. Pérez-García, E. Salas, C. González-Martín, C. Castillo, M. J. Polanco, G. Herradón and L. Morales

Madrid, Spain

* E-mail: laguacil@ceu.es

The first 10% of the full text of this article appears below.

Peripheral tetrodotoxin (TTX) has been proposed for the treatment of several types of pain, and thus i.m. TTX is currently being evaluated in patients with severe cancer pain.1 In some animal studies, it appears that inflammatory pain may also be responsive to the antinociceptive effect of TTX, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?